← Back to Clinical Trials
Recruiting Phase 2 NCT06647550
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Trial Parameters
Condition Type 2 Diabetes Mellitus (T2DM)
Sponsor Hyundai Pharm
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 160
Sex ALL
Min Age 19 Years
Max Age 75 Years
Start Date 2024-12-12
Completion 2025-03-31
Interventions
HD-6277 100mgHD-6277 50mgHD-6277 25mg
Brief Summary
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Eligibility Criteria
Inclusion Criteria: * Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening. Exclusion Criteria: * Type 1 diabetes or another immune-mediated diabetes syndrome * BMI: \> 40 kg/m2 * C-peptide: \< 0.5ng/mL
Related Trials
NCT06716203
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
View Trial →
NCT07069166
Para-Probiotic Oral Care in Periodontal Patients With Type 2 Diabetes
View Trial →
NCT07163975
Complete Pulpotomy and Root Canal Treatment Patients With Irreversible Pulpitis With Type 2 Diabetes
View Trial →